Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.kint.2021.03.009 http://scihub22266oqcxt.onion/10.1016/j.kint.2021.03.009 33774082!7992297!33774082     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Int 2021 ; 99 (6): 1470-1477 Nephropedia Template TP {{tp|p=33774082|t=2021. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection |pdf=|usr=}}{{33774082}} gab.com Text Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection JO: Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=33774082 #FOAvip Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity. Twit Text FOAVip Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection ????Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=33774082 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33774082 #FOAvip English Wikipedia <ref>{{Cite pmid|33774082}}</ref> Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection #MMPMID33774082 Clarke CL; Prendecki M; Dhutia A; Gan J; Edwards C; Prout V; Lightstone L; Parker E; Marchesin F; Griffith M; Charif R; Pickard G; Cox A; McClure M; Tedder R; Randell P; Greathead L; Guckian M; McAdoo SP; Kelleher P; Willicombe M Kidney Int 2021[Jun]; 99 (6): 1470-1477 PMID33774082show ga Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity. |Antibodies, Viral/*analysis[MESH] |COVID-19 Testing[MESH] |COVID-19/*immunology[MESH] |Female[MESH] |Humans[MESH] |Immunity[MESH] |Kidney Failure, Chronic/*therapy[MESH] |Male[MESH] |Pandemics[MESH] |Polymerase Chain Reaction[MESH] |Reinfection[MESH] |Renal Dialysis/*adverse effects[MESH] |SARS-CoV-2/*immunology/isolation & purification[MESH]Longevity of SARS-CoV-2 immune responses in hemodialysis patients and (epmc).pdf DeepDyve Pubget Overpricing